Weather , , 0°C

Synovial Sarcoma Pipeline Insight, 2020

 Breaking News
  • No posts were found

Synovial Sarcoma Pipeline Insight, 2020

July 17
14:08 2020
Synovial Sarcoma Pipeline Insight, 2020

(Albany, US), DelveInsight has launched a new report on Synovial Sarcoma Pipeline

Synovial Sarcoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Synovial Sarcoma market. A detailed picture of the Synovial Sarcoma pipeline landscape is provided, which includes the disease overview and Synovial Sarcoma treatment guidelines. The assessment part of the report embraces in-depth Synovial Sarcoma commercial assessment and clinical assessment of the Synovial Sarcoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Synovial Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8–10% of all soft tissue sarcomas (STS). Despite its name, synovial sarcoma is not related to the synovial tissues that are a part of the joints. The disease starts most commonly in the legs or arms, but can appear in any part of the body. Being a high-grade tumor, it spreads to distant sites in about half of the cases. Synovial sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated. The exact underlying cause of synovial sarcoma is poorly understood. However, studies indicate that translocation between chromosome X and chromosome 18 appears to play a role in the development of synovial sarcoma. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. In the early stages of the condition, synovial sarcoma may cause no noticeable signs or symptoms but as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit the range of motion or cause numbness and/or pain if it presses on nearby nerves.

 

Request for Free sample page:-  https://www.delveinsight.com/sample-request/synovial-sarcoma-pipeline-insight

Synovial Sarcoma Pipeline development activities

The report provides insights into: 

  • All of the companies that are developing therapies for the treatment of Synovial Sarcoma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Synovial Sarcoma treatment.
  • Synovial Sarcoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Synovial Sarcoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 

Synovial Sarcoma Emerging Drug Analysis

The landscape of Synovial Sarcoma market is speculated to change in the coming years owing to the launch of several upcoming therapies. A significant amount of research and developmental activities over the past several years have led to the gradual emergence of more effective and less toxic treatment modalities in Synovial Sarcoma (SS) patients. Although at present Pazopanib remains the only targeted drug approved for the treatment of soft tissue sarcomas in the advanced settings after failure of standard cytotoxic therapy, but the situation is will undergo a dynamic change during the forecast period. Advenchen Laboratories, Adaptimmune, and Epizyme are the top players that are actively working on development of therapies for Synovial Sarcoma.

Marketed Drugs included in the report

  • Yondelis (Trabectadin Co.)
  • Pazopanib (Novartis Co.)

 

Emerging drugs included in the report

  • Tazemetostat (Epizyme Inc)
  • ADP-A2M4 (Adaptimmune)
  • Anlotinib (Al3818)- (Advenchen Laboratories)

 

Table of content

1. Report Introduction

2. Synovial Sarcoma

3. Synovial Sarcoma Current Treatment Patterns

4. Synovial Sarcoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Synovial Sarcoma Late Stage Products (Phase-III)

7. Synovial Sarcoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Synovial Sarcoma Discontinued Products

13. Synovial Sarcoma Product Profiles

14. Synovial Sarcoma Key Companies

15. Synovial Sarcoma Key Products

16. Dormant and Discontinued Products

17. Synovial Sarcoma Unmet Needs

18. Synovial Sarcoma Future Perspectives

19. Synovial Sarcoma Analyst Review 

20. Appendix

21. Report Methodology

22. About DelveInsight

Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Calendar

April 2021
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  

Categories